Dweve
Weaving Intelligence

ENGLISH EDITION · JULY 2026

MARKETING BROCHURE · 20 PAGES

Dweve for Pharma and life sciences

A standalone visual briefing for pharma and life sciences leaders, practitioners, technology teams, and reviewers.

VISUAL BRIEFING

PHARMA AND LIFE SCIENCES LEADERS, DOMAIN OWNERS, OPERATIONS, TECHNOLOGY, RISK, AND ASSURANCE TEAMS

ENGLISH



Scope and prove one accountable pharma and life sciences workflow.

SC10

THE PROPOSITION

One pharma and life sciences decision people can answer for

Existing LIMS, ERP, and QMS systems keep working. Dweve wraps them in a deterministic decision layer that records every assay, every method, and every QP signature as the release happens.

How to read this visual: follow a batch release case through the proposition.

DECISION

Read the promise against the operating reality

Existing LIMS, ERP, and QMS systems keep working. Dweve wraps them in a deterministic decision layer that records every assay run, every validated method, and every QP signature as the release happens. The replay packet is the audit artefact.

Existing LIMS, ERP, and QMS systems keep working. Dweve wraps them in a deterministic decision layer that records every assay, every method, and every QP signature as the release happens.

- Purpose
- Source
- Rule
- Decision

QUESTION TO CARRY

Which part of this proposition changes the outcome people receive today?

WHERE TO BEGIN

Six sector conversations worth having

A sector brochure must stand on its own. These are practical starting points, not a promise that every workflow should use AI.

How to read this visual: follow a batch release case through where to begin.

MECHANISM

Choose a starting point with a real consequence

Clinical operations is the workflow most damaged by EDC, CTMS, and eTMF systems that were never meant to agree. Dweve wraps the trial in a deterministic decision layer so every enrolment, every dose, every adverse event, and every protocol amendment sits in the same packet the QP signs at release.

A head of quality does not buy a platform. She survives an inspection. EMA GxP rules, 21 CFR Part 11, and the EU AI Act each want the same thing: the batch, the assay, the rule, the qualified person, and the signature of every release decision. Today that record lives in LIMS, ERP, QMS, and email threads that were never meant to agree.

- Batch release
- Trial review
- Stability
- Safety signals

QUESTION TO CARRY

Which bounded workflow has a real owner and a consequence worth improving?

THE CURRENT ESTATE

Keep the systems that already hold operational truth

The accountable layer connects to systems of record and control without pretending to replace every specialist system.



How to read this visual: follow a batch release case through the current estate.

DECISION

Keep existing operational truth in the picture

Keep the batch, assay, governing rule, qualified person, and model version together at release. The GxP-validated decision record is ready for an EMA inspection, FDA 483 response, or PSUR cycle, without rebuilding it after the fact.

Every batch release is appealable. The same record the QP signed is the record you can question through your pharmacist or doctor. If you have an adverse event, the report flows into the same packet the EMA reviews.

- Authoritative estate
- Bounded decision layer
- Human and system hand-off
- Purpose

QUESTION TO CARRY

Which systems remain authoritative, and what may the new layer change?

REPRESENTATIVE WORKFLOW

A sector decision moves through one visible chain

The exact systems and roles change by organisation. The responsibility pattern remains inspectable.

How to read this visual: follow a batch release case through representative workflow.

MECHANISM

Follow one decision without skipping a boundary

Pick one workflow: batch release, dose-response analysis, stability tracking, or pharmacovigilance triage. Run it with your own assay data and watch the review packet assemble as the work moves. Managed through Fabric on the public Dweve Mesh, on your hardware, or air-gapped.

Every batch release, dose-response analysis, and stability timepoint leaves a signed packet: the assay source, the validated method, the QP, and a bit-exact replay. The inspector opens one file and watches the same decision come back.

- Receive
- Ground
- Recommend
- Authorise

QUESTION TO CARRY

Where do source, rule, computation, review, and action join?

SECTOR ASSURANCE

Different people need different proof from the same event

A single technical log rarely answers every question. Design the record around the people who will actually use it.



How to read this visual: follow a batch release case through sector assurance.

DECISION

Give each reader the proof they actually need

An adverse event report is no longer a black box. The intake, seriousness classification, causality assessment, and PSUR contribution each have a named reviewer, a timestamp, and a rule attached.

You do not need to fight a chat box to question a medicine. The packet is in plain language and the QP, the batch, and the assay are named.

- A reason and a route to challenge
- State, authority, and next action
- A resolvable evidence packet
- Purpose

QUESTION TO CARRY

Can the person, operator, and reviewer each obtain the proof they need?

USE AND FIT

Where pharma and life sciences work can earn its place

Start with responsibilities that have a real owner, useful sources, and a consequence worth improving.



How to read this visual: follow a batch release case through use and fit.

MECHANISM

Separate useful scope from attractive distraction

Pharmacovigilance signal detection is the workflow most damaged by float drift and E2B version skew. Dweve runs the signal scoring on integer arithmetic, pins to a specific EBGM model version, and ships the same flag every time. The packet is the audit artefact.

Two questions decide procurement: where does it run, and which rules does it satisfy. It runs managed through Fabric on the public Dweve Mesh, on your GxP-qualified hardware, or fully air-gapped, with no re-platforming between tiers. GDPR, GxP, 21 CFR Part 11, and the EU AI Act are design constraints the platform satisfies by construction.

- Batch release
- Trial review
- Stability
- Safety signals

QUESTION TO CARRY

Where does this earn a place, and where should it deliberately not be used?

THE PATH

How pharma and life sciences work moves from question to decision

A focused engagement should make the next decision easier, not create a larger promise.



How to read this visual: follow a batch release case through the path.

WHY THIS SHAPE WORKS

The workflow, operating boundary, evidence, and decision criteria are considered together from the start.

DECISION

Make every stage earn the next one

The release decision stays inside your jurisdiction. The same platform scales from a single pilot trial to a full commercial manufacturing pipeline without re-platforming.

Validated method HPLC-2024-v3 (ICH Q2 R2 compliant) measured the cetirizine assay at 99.4 percent, within the registered spec of 95.0 to 105.0. The batch passed dissolution, related substances, and identification tests per the marketing authorisation EU/1/90/036. The qualified person Dr. A. Jansen signed the release on 2026-06-12. The same decision replays bit-identical.

- Purpose
- Rule
- Authority
- Evidence

QUESTION TO CARRY

What evidence must exist before the scope is allowed to grow?

THE VALUE PICTURE

pharma and life sciences work seen from three responsibilities

Good AI work must make sense to the person using it, the team operating it, and the people reviewing it.

How to read this visual: follow a batch release case through the value picture.

PRIMARY READER

Pharma and life sciences leaders, domain owners, operations, technology, risk, and assurance teams

The first conversation.

DECISION SUPPORTED

Scope and prove one accountable pharma and life sciences workflow.

The next useful step.

MECHANISM

Read the same outcome from several responsibilities

Three operating models, one evidence architecture. Managed Fabric runs on the public Mesh. Licensed operation brings direct products to GxP-qualified hardware. Air-gapped operation protects the most sensitive trial data. Each model keeps decisions and evidence inside its declared trust boundary.

Integrate via REST or gRPC against a typed OpenAPI 3.1 surface. Managed through Fabric on the public Dweve Mesh for pilots. Licensed for GxP-qualified hardware. Air-gapped for the most sensitive trial data. Same API, same trace format, same replay packets across all three.

- Purpose
- Rule
- Authority
- Source

QUESTION TO CARRY

Can the same result satisfy its user, operator, and reviewer?

THE OPERATING MODEL

The control model around pharma and life sciences work

A credible proposition connects the visible result to the less visible responsibilities underneath it.



How to read this visual: follow a batch release case through the operating model.

DECISION

Name the controls behind the simple interface

When your pharmacy uses Dweve, your medicine is not a black box. It is tied to a released batch, an assay result, and a named qualified person who signed the release. If you ask why, the answer is on the leaflet.

Every numerical computation in the assay and stability path is verified against MPFR at 256-bit precision. The published result is 0 ULP, correctly rounded across the documented input domain, with property-based tests driving the corners on every release.

- Purpose
- Source
- Rule
- Decision

QUESTION TO CARRY

Who owns each control when the interface appears simple?

THE RESPONSIBILITY FLOW

People, pharma and life sciences work, and evidence move together

The work becomes easier to govern when each stage leaves a clear hand-off.



How to read this visual: follow a batch release case through the responsibility flow.

MECHANISM

Keep every hand-off attached to an owner

Most people open managed Fabric in a browser and start without an infrastructure project. Organisations that need direct product operation inside their own perimeter move to a licensed deployment. Workflow and evidence contracts remain portable, while product access, keys, patches, logs, and operating responsibility change.

A medicine reaches you through a chain of checks. Dweve keeps the released batch, test result, and person who signed the release together, so the explanation does not disappear inside a system you cannot inspect.

- Purpose
- Rule
- Authority
- Evidence

QUESTION TO CARRY

Is every hand-off visible, bounded, and assigned to an owner?

SOURCE TO RESULT

pharma and life sciences work: from authoritative source to result

The work stays explainable when source identity, transformation, decision, and hand-off remain visible between systems.



How to read this visual: follow a batch release case through source to result.

DECISION

Keep the basis visible as the work changes form

The trial, the release, and the post-market surveillance all draw from one packet source. The EMA inspector opens one file per decision.

Batch stability moves through long-term, intermediate, accelerated, and photostability conditions per ICH Q1A. Every timepoint is recorded with its protocol, the lab, the operator, and the result. The replay reconstructs the exact stability profile years later.

- Identify
- Prepare
- Apply
- Review

QUESTION TO CARRY

Can the result still be connected to the exact basis that shaped it?

EVIDENCE PACKET

The evidence pharma and life sciences work leaves with the work

Capture enough to explain the result, inspect authority, investigate failure, and make the next decision without rebuilding the story from memory.



How to read this visual: follow a batch release case through evidence packet.

MECHANISM

Preserve the record needed by the next question

Bit-exact replay for dose-response, batch stability, and pharmacovigilance triage. 21 CFR Part 11 compliant signatures, ICH E2B aware, EU-sovereign. Integrate via API, host in the EU, or run air-gapped for the most sensitive trial data.

Every dose-response analysis, exposure-response model, and interim look runs on a deterministic engine. Bit-exact replay across machines and releases. The same curve on the trial sponsor laptop, the CRO server, and the EMA submission.

- Purpose
- Basis
- Authority
- Action

QUESTION TO CARRY

Does the retained record answer the next difficult question without reconstruction?

DEPLOYMENT CHOICE

Choose the operating posture for pharma and life sciences work

Location is only one dimension. Decide who operates, who holds keys, which dependencies exist, how updates arrive, and what continuity requires.



How to read this visual: follow a batch release case through deployment choice.

DECISION

Compare operating responsibility, not location alone

Determinism is asserted in the suite, not promised in prose. The same oracle run on your hardware produces the same answer as on ours.

Managed customers use Fabric, its business API and Agent SDK on the public Dweve Mesh. A licensed deployment adds direct operation of Core and the platform products on customer-controlled infrastructure. Key custody, updates, logs, product access, and source rights follow that boundary.

- Begin through managed Fabric
- Run on customer infrastructure
- Close the environment
- Purpose

QUESTION TO CARRY

Who holds infrastructure, keys, updates, logs, recovery, and the exit path?

WHAT TO LOOK FOR

Signals that pharma and life sciences work is earning trust

Progress is a useful outcome under understood control, supported by reviewable evidence.



How to read this visual: follow a batch release case through what to look for.

MECHANISM

Use signals that can change the next decision

The decision layer never crosses a trust boundary that fails the GxP or 21 CFR Part 11 rules. The same topology ships on all three postures.

The assay is the easy part. Reconstructing the why of every batch release six months later, in front of an EMA inspector, is the hard part.

- Useful
- Controlled
- Provable
- Purpose

QUESTION TO CARRY

Which signals would change the next decision rather than merely impress the room?

HONEST LIMITS

Test how pharma and life sciences work fails before the first success demo

Visible failure is more useful than a polished result whose limits remain unknown.



How to read this visual: follow a batch release case through honest limits.

DECISION

Design the failure before presenting the success

The trace still records inputs, operations, and policy decisions, but does not pin every sampling choice to a fixed result. Useful for development and exploratory work where the audit record matters more than exact reproduction.

Choose managed Fabric on the public Dweve Mesh, direct licensed operation on your infrastructure, or an isolated licensed perimeter. Workflow and evidence contracts remain portable; product access, keys, patches, logs, source rights, and operational responsibility change.

- Method deviation
- Safety signal
- Missing signature

QUESTION TO CARRY

What happens when a source, permission, target, model, or supplier is unavailable?

ACCEPTANCE PATH

Close the pharma and life sciences work proof with a decision

Agree the decision path before the demonstration so a strong or weak result can change what happens next.



How to read this visual: follow a batch release case through acceptance path.

MECHANISM

Close the proof with an owned decision

Policy evaluation in Lattice and proof generation in AION are pure functions of their inputs. Both run with no network access.

Shuttle is a hardware-target option inside the air-gapped posture. It runs the same binaries as every other posture. The FPGA backend in Core handles the compute path; the rest of the stack is unchanged.

- Baseline
- Accept
- Exercise
- Review

QUESTION TO CARRY

Are success, counter-metrics, failure cases, and stop conditions agreed first?

ADOPTION

Adopt pharma and life sciences work through owned choices

Move from one bounded result to a repeatable operating capability without making the scope vague.

How to read this visual: follow a batch release case through adoption.

DECISION

Expand only what proved reusable

Start in a European region, move the same workflow into your own environment, or isolate it completely. The operating model changes; the way people review and approve work does not.

Start in managed Fabric: open a browser, sign in, and ask. If your organisation later needs direct product operation inside its own perimeter, use a licensed transition plan that carries the workflow and evidence contracts into customer-controlled infrastructure.

- Prove one workflow
- Own the operation
- Repeat the pattern
- Add responsibility

QUESTION TO CARRY

What can be reused safely, and what requires a new decision and proof?

WHAT TO PREPARE

What to bring to the pharma and life sciences working session

A small amount of real context produces a better conversation than a broad catalogue of hypothetical features.



How to read this visual: follow a batch release case through what to prepare.

KEEP IT BOUNDED

Sensitive production data is not required for the first conversation. Bring representative material and the rules that define a useful result.

MECHANISM

Bring enough reality to make the session useful

Fabric is the app you actually use. You log in, start a conversation, upload documents, or build a small workflow. Behind the scenes the model powers the answers, the network handles the compute, and the agents do the organizing, but you never have to configure any of that. The trace is always there if you want to see how an answer was reached.

A trace on every decision means a real question comes back with the source it used, the rule it applied, the owner who signed, and a sealed record you can replay. Here is the shape of that evidence. The example is illustrative until your own data is connected.

- Bring one workflow
- Bring representative sources
- Agree the proof
- Purpose

QUESTION TO CARRY

Which real sources, rules, owners, and examples will make the first session honest?

THE INVITATION

Continue the pharma and life sciences work conversation

Scope a briefing, demonstration, or proof around the workflow and decision that matter to your organisation.



CONTINUE ONLINE

dweve.com/contact

Current route and contact choices

START A CONVERSATION

Continue through the current contact page

Scope a workflow or ask a technical question, then use the contact page to begin.

START	**dweve.com/contact**	Use the maintained public contact route
BRING	**One bounded question**	Workflow, audience, decision, and desired evidence
CHOOSE	**Briefing · demonstration · PoV**	Select the smallest useful next step
VERIFY	**Current scope and terms**	Confirm availability, pricing, and responsibilities before commitment

DECISION

Turn the brochure into one bounded next step

The access model decides who operates the products, who holds the keys, and where the boundary sits. Workflow and evidence contracts remain portable, but rights are not identical.

No workflow rebuild is required, but the access boundary changes. Managed customers use Fabric and its business surfaces; licensed customers operate the products directly.

- Start: dweve.com/contact
- Bring: One bounded question
- Choose: Briefing · demonstration · PoV
- Verify: Current scope and terms

QUESTION TO CARRY

What is the smallest useful next conversation Dweve should prepare?